These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 20698202)

  • 1. Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China.
    Qun W; Tao Y
    Hepatogastroenterology; 2010; 57(99-100):426-9. PubMed ID: 20698202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A case report--intrahepatic arterial infusion with CDDP and S-1 administration can elicit long-term survival for the patient with recurrenced intrahepatic cholangiocarcinoma after resection].
    Tanida T; Tanemura M; Kobayashi S; Wada H; Marubashi S; Eguchi H; Takeda Y; Umeshita H; Mori M; Doki Y; Nagano H
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2729-31. PubMed ID: 21224694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A case of intrahepatic cholangiocarcinoma successfully treated by hepatic arterial infusion chemotherapy].
    Kudoh K; Doi K; Ohchi T; Ogata K; Matsuo A; Ohtao R; Sugimura H; Muranaka T
    Gan To Kagaku Ryoho; 2007 Nov; 34(12):1993-5. PubMed ID: 18219876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic arterial infusion of mitomycin C with degradable starch microspheres for unresectable intrahepatic cholangiocarcinoma.
    Shitara K; Ikami I; Munakata M; Muto O; Sakata Y
    Clin Oncol (R Coll Radiol); 2008 Apr; 20(3):241-6. PubMed ID: 18222071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report.
    LaRocca RV; Hicks MD; Mull L; Foreman B
    J Gastrointest Cancer; 2007; 38(2-4):154-6. PubMed ID: 19089671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A case report: successful resection of advanced intrahepatic cholangiocarcinoma responding to preoperative hepatic artery infusion of 5-FU].
    Hasuike Y; Motoori M; Hattori T; Fujita J; Mishima H; Sawamura T; Nishishou I; Kikkawa N; Sai H; Hosoki T; Mitomo M
    Gan To Kagaku Ryoho; 1999 Oct; 26(12):1909-12. PubMed ID: 10560423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of successful management of advanced cholangiocellular carcinoma by repeated hepatic resection].
    Nakano H; Sasaki Y; Imaoka S; Furukawa H; Ishikawa O; Kabuto T; Kameyama M; Hiratsuka M; Ohigashi H; Nakamori S; Yasuda T; Iwanaga T
    Gan To Kagaku Ryoho; 1996 Sep; 23(11):1603-6. PubMed ID: 8854817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery.
    Todoroki T
    Hepatogastroenterology; 2000; 47(33):644-9. PubMed ID: 10919004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Successful treatment for advanced cholangiocellular carcinoma with intrahepatic metastasis and/or portal vein tumor thrombi by intraarterial chemotherapy combined with 5-fluorouracil, adriamycin and cisplatin (FAP)--two cases report].
    Wada H; Nagano H; Dono K; Kondo M; Yamamoto T; Ota H; Nakamura M; Yoshioka S; Damdinsuren B; Yubo Y; Marubashi S; Miyamoto A; Umeshita K; Nakamori S; Sakon M; Monden M
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1711-3. PubMed ID: 15553691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
    Kudo M; Ueshima K
    Oncology; 2010 Jul; 78 Suppl 1():154-66. PubMed ID: 20616599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma.
    Huether A; Höpfner M; Baradari V; Schuppan D; Scherübl H
    Biochem Pharmacol; 2007 May; 73(9):1308-17. PubMed ID: 17266941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review).
    Ibrahim N; Yu Y; Walsh WR; Yang JL
    Oncol Rep; 2012 May; 27(5):1303-11. PubMed ID: 22323095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors of intrahepatic cholangiocarcinoma after hepatic resection: univariate and multivariate analysis.
    Hanazaki K; Kajikawa S; Shimozawa N; Shimada K; Hiraguri M; Koide N; Adachi W; Amano J
    Hepatogastroenterology; 2002; 49(44):311-6. PubMed ID: 11995440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Resection of cholangiolocellular carcinoma successfully responding to neoadjuvant hepatic arterial infusion chemotherapy - report of a case].
    Nakayama Y; Nakamura N; Ito T; Matsubayashi J; Yogo A; Kitou Y; Hanamoto K; Ura K; Taira K; Oe H; Yoshikawa A; Mitsuyoshi A; Ishigami S; Shirase T; Doi R
    Gan To Kagaku Ryoho; 2012 Jul; 39(7):1155-7. PubMed ID: 22790060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model.
    Heravi M; Tomic N; Liang L; Devic S; Holmes J; Deblois F; Radzioch D; Muanza T
    Anticancer Drugs; 2012 Jun; 23(5):525-33. PubMed ID: 22357220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of unresectable cholangiocellular carcinoma treated with surgery followed by combination chemotherapy].
    Hayashi N; Hasuike Y; Fukuchi N; Kida H; Tujie M; Yoshida T; Ebisui C; Sakita I; Koshino T; Izumiyama K; Koro T; Fujimoto T
    Gan To Kagaku Ryoho; 2005 Oct; 32(11):1852-4. PubMed ID: 16315961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
    Adnane L; Trail PA; Taylor I; Wilhelm SM
    Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma.
    Poggi G; Montagna B; Melchiorre F; Quaretti P; Delmonte A; Riccardi A; Tagliaferri B; Sottotetti F; Di Cesare P; Stella MG; Villani L; Zorzetto M; Greco G; Cornalba G; Bernardo G
    Anticancer Res; 2011 Nov; 31(11):3927-33. PubMed ID: 22110221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.